Kinesiophobia, Pain, Balance, Quality of Life and Mental Status in Hemodialysis Patients

November 22, 2024 updated by: Merve Firat, Kirsehir Ahi Evran Universitesi

Investigation of the Relationship Between Kinesiophobia and Pain, Balance, Quality of Life and Mental Status in Hemodialysis Patients

The aim of our study was to investigate the relationship between kinesiophobia and pain, balance, physical performance, quality of life and mental status in patients receiving hemodialysis.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

32

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with end-stage renal disease receiving hemodialysis will be enrolled in the study.

Description

Inclusion Criteria:

  • Patients with end stage renal disease receiving hemodialysis
  • Receiving hemodialysis for more than 3 months
  • Being clinically stable
  • Volunteering to participate in this stud

Exclusion Criteria:

-Having musculoskeletal disorders that may affect physical performance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Hemodialysis patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Kinesiophobia
Time Frame: Day 1
It will be evaluated with the Tampa Kinesiophobia scale.The total score ranges from 17-68, with a score above 37 indicating a high degree of kinesiophobia.
Day 1
Pain
Time Frame: Day 1
Will be evaluated with a numeric rating scale. Higher scores indicate worse outcomes.
Day 1
Balance
Time Frame: Day 1
It will be assessed with a timed up and go test
Day 1
Physical performance
Time Frame: Day 1
It will be evaluated with five-repetition sit-to-stand test
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life
Time Frame: Day 1
It will be evaluated with the Short Form-36 Quality of Life scale.The subscales rate health from 0 to 100, with 0 indicating poor health and 100 indicating good health.
Day 1
Mental health
Time Frame: Day 1
It will be assessed using the Hospital Anxiety and Depression scale. The lowest score they can get from both subscales is 0 and the highest score is 21.High scores indicate high levels of anxiety and depression
Day 1
Comorbidity level
Time Frame: Day 1
It will be evaluated with the Charlson Comorbidity Index. Total score is between 0-37. Higher scores indicate worse outcomes and higher risk of death.
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kirsehir Ahi Evran Universitesi

Investigators

  • Study Chair: Yusuf Topal, Kirsehir Ahi Evran University
  • Study Chair: Aydin Guclu, Kirsehir Ahi Evran University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 18, 2024

Primary Completion (Estimated)

September 1, 2025

Study Completion (Estimated)

January 1, 2026

Study Registration Dates

First Submitted

November 6, 2024

First Submitted That Met QC Criteria

November 18, 2024

First Posted (Actual)

November 20, 2024

Study Record Updates

Last Update Posted (Estimated)

November 25, 2024

Last Update Submitted That Met QC Criteria

November 22, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024-12/101

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemodialysis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe